Colleen Koski

Recent Posts

Crystal Research Associates to Sponsor 6th Annual OneMedForum

Posted by Colleen Koski

October 16, 2012 at 12:22 PM

Partnership with OneMedPlace provides research and expanded media coverage to client companies

Read More

Topics: Crystal Research Associates, OneMedForum

NEW REPORT: Quarterly Update on Neonode Inc. (NEON-NASDAQ)

Posted by Colleen Koski

October 9, 2012 at 10:01 AM

Read More

Topics: Neonode Inc., touch technology, zForce, New Research

New Research Available on Local Corporation (LOCM-NASDAQ)

Posted by Colleen Koski

August 29, 2012 at 10:14 AM

Yesterday, we issued an Executive Informational Overview® on Local Corporation (LOCM-NASDAQ), a provider of digital marketing products designed to connect local businesses with online and mobile consumers. 

Local Corporation has expertise in helping small businesses develop and maintain a sophisticated online presence in order to be easily found by consumers, both on their own web properties and on major search engines. Its platform includes rich media ad creative, local business directory and product search technologies, mobile capabilities, search engine optimization (SEO), web hosting, social media services, daily deals, and a loyalty/rewards program, among other products and services.

Read More

Topics: Local Corporation, New Research

GenSpera Receives FDA Clearance to Initiate Phase II Clinical Trials in Prostate Cancer

Posted by Colleen Koski

August 2, 2012 at 3:01 PM

GenSpera, Inc. (GNSZ-OTC) is one step closer to initiating its planned Phase II human clinical trial of its lead compound, G-202, in prostate cancer patients. On Tuesday, July 31, 2012, GenSpera announced that the U.S. Food and Drug Administration (FDA) cleared its Phase II trial for initiation. The Company expects to commence patient enrollment once it receives approval by the Institutional Review Boards for its six trial sites in the U.S. and the UK. The study could include up to 40 prostate cancer patients who failed previous hormonal therapy. GenSpera expects prostate cancer patients to particularly benefit from G-202 due to the drug’s ability to target slow-growing cancer cells.

Read More

Topics: GenSpera, Prostate Cancer

Second Quarter FY2012 Financial Results and Business Update on LRAD Corp. (LRAD-NASDAQ)

Posted by Colleen Koski

June 21, 2012 at 10:12 AM

On June 21, 2012, Crystal Research issued a Quarterly Update on LRAD Corp. (LRAD-NASDAQ), a company developing and marketing acoustic hailing devices (AHD) that support the delivery and intelligibility of audio broadcasts over long ranges. The 12-page Update is available here.

Read More

Topics: LRAD

LRAD Corp.'s Acoustic Technology To Be Used at 2012 NATO Summit

Posted by Colleen Koski

May 16, 2012 at 3:39 PM

The Chicago Police Department has announced that it will use LRAD Corp.'s (LRAD-NASDAQ) long-range acoustic devices (LRAD) to communicate to crowds during the 2012 NATO Summit in Chicago. This is one of many safety and security measures the city has put in place in preparation for the event, which begins Sunday, May 20, 2012. Various protests and demonstrations are expected leading up to and throughout the Summit. 

Read More

Topics: LRAD

BELLUS Health Reports 1Q Financial Results, Provides Corporate Update

Posted by Colleen Koski

May 15, 2012 at 6:05 PM

May 15, 2012 (CNW), LAVAL, QC-- 

Read More

Topics: Bellus Health, KIACTA, Pharmascience, VIVIMIND

LRAD Corp. Receives $1.7 Million LRAD-RX Order for Asian Maritime Security

Posted by Colleen Koski

May 15, 2012 at 5:05 PM

May 15, 2012 (Marketwire), SAN DIEGO, CA-- 

Read More

Topics: LRAD

Crystal Research CEO Jeffrey Kraws Appointed Chairman of the Board, Synthetic Biologics (SYN-NYSE Amex)

Posted by Colleen Koski

May 11, 2012 at 12:25 PM

ANN ARBOR, Mich.May 11, 2012  /PRNewswire/ -- 

Synthetic Biologics, Inc. (SYN-NYSE Amex), a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses, announced today that to improve its corporate governance and strengthen the Board, it has split the roles of Chairman and Chief Executive Officer, and appointed Jeffrey J. Kraws to serve as its independent, non-executive Chairman of the Board. Mr. Kraws has served on the Company's Board of Directors since January 2006, and will continue to serve on the Compensation and Nominations Committees.

Read More

Topics: Crystal Research Associates, Synthetic Biologics

MedPro and Unilife Featured in Drug Development & Delivery Magazine

Posted by Colleen Koski

May 11, 2012 at 9:20 AM

MedPro Safety Products, Inc. (MPSP-OTC.BB) and Unilife Corporation (UNIS-NASDAQ) were featured in the May 2012 edition of Drug Development & Delivery in an article, entitled "Prefilled Syringes - A Container of Choice for Pharma." Drug Development & Delivery interviewed leading players in the prefilled syringe market to learn about their products and how each company is addressing pharma’s needs for safety, ease of use, cost, and product differentiation. 

Read More

Topics: Unilife Corp., MedPro, Prefilled Syringe

Israeli Government Awards T3 Motion 2-Year Electric Vehicle Contract

Posted by Colleen Koski

May 9, 2012 at 10:46 AM

Yesterday, T3 Motion, Inc. (TTTM-NYSE Amex) announced that the Israeli government has awarded T3 Motion and its Israeli distributor, Yaum Ltd., a two-year contract for T3 Series Electric Stand-up Vehicles (ESV). The T3 ESV is now the default personal mobility vehicle for all Israeli government agencies.

Read More

Topics: T3 Motion

Jeff Kraws Weighs In on Supreme Court Victory for Generic Drug Makers

Posted by Colleen Koski

April 19, 2012 at 3:03 AM

Novo Nordisk PrandinYesterday, Crystal Research CEO Jeffrey Kraws and NPR's correspondent Yuki Noguchi discussed the impact of a U.S. Supreme Court decision that allows generic drug makers to challenge brand-name rivals suspected of overstating the reach of their patents in regulatory filings. The full audio clip and transcript are available here.

Read More

Topics: Crystal Research Associates, Novo Nordisk, generic drugs

APDN's Revenues Rise 63% in the First Quarter FY 2012

Posted by Colleen Koski

March 6, 2012 at 11:44 AM

Yesterday, we released a Quarterly Update on Applied DNA Sciences, Inc. (APDN-OTC), which includes an overview of the Company's first quarter FY 2012 financial results as well as a business update.

Read More

Topics: Applied DNA Sciences

Independent Equity Research Report on LRAD Corp. (LRAD-NASDAQ)

Posted by Colleen Koski

February 13, 2012 at 7:54 PM

Crystal Research has initiated coverage on LRAD Corp. (LRAD-NASDAQ) with the publication of a 64-page Executive Informational Overview® available here.

LRAD Corp. (“the Company”) develops and markets long-range acoustic hailing devices (AHDs) that are designed to improve the delivery and intelligibility of audio broadcasts. The Company’s Long Range Acoustic Device® (LRAD®) technology uses advanced sound reproduction technologies and novel acoustic materials to broadcast authoritative and highly intelligible instructions, warnings, alarms, and other sounds over several miles.

LRAD-Navy

LRAD® improves upon traditional speaker systems and megaphones by directing sound only where needed. Similar to a spotlight, which produces an intense beam of targeted light, each LRAD® system delivers a focused, directional audio broadcast. The beam width, frequency range, and maximum continuous output of LRAD® devices can be adjusted to target individuals, small groups, and large crowds at various ranges.

LRAD Corp.’s versatile product portfolio has a broad range of applications, including military, wildlife and asset protection, public safety/law enforcement, and commercial security. 

Military Opportunities

At present, LRAD Corp. believes that its largest market opportunity is with the U.S. military. The Company is working with Kongsberg Gruppen ASA (KOG-OSE)—a global military and defense contractor—to develop Common Remotely Operated Weapon Stations (CROWS) that provide soldiers escalation of force options and the ability to communicate to targets (via LRAD®) from within the safety of their armored vehicles.

Kongsberg currently supplies its PROTECTOR CROWS to the U.S. Army under a five-year framework agreement. As the agreement comes to a close, the Army has disclosed that the upcoming CROWS III contract is valued at $970 million (~3,000 units). LRAD Corp. and Kongsberg are working on a submission for the upcoming CROWS III contract and seek to obtain an initial order for field testing.

As well, the U.S. Army has issued a public Request for Information (RFI) regarding 6,350 AHDs. LRAD Corp. is actively pursuing this opportunity and is hopeful that the process could advance to the formal Request for Proposal (RFP) stage in 2012.

Wildlife and Asset Preservation

LRAD® technology is proving to be effective at preserving both wildlife and critical assets at airports, air bases, harbors, wind farms, tailing ponds, and other facilities. The Company reports that its devices have been installed in multiple mining operations for over two years and have reduced bird deaths from thousands annually to less than 20 per year. LRAD® may also benefit solar farms, nuclear power facilities, agricultural operations, fisheries, and other industries that have wildlife preservation concerns. The video below provides a demonstration of the ability of LRAD to deter wildlife from control zones.

The Company aims to capitalize on successful trials and opening orders to date to further penetrate the wildlife and asset preservation market, particularly airports and clean/alternative energy applications (e.g., wind farms). From 1990 to 2009, bird strikes resulted in nearly 425,000 hours of aircraft downtime and roughly $375 million in monetary losses (Source: the Federal Aviation Administration). The U.S. Air Force has reported that it spends approximately $35 million annually to repair aircraft damage caused by bird strikes. Moreover, wind turbines cause roughly 440,000 bird deaths each year in the U.S. (Source: the U.S. Fish and Wildlife Service).

Public Safety/Law Enforcement

In public safety, LRAD® systems can be an effective mass communications tool to quickly issue warnings, instructions, and directions during natural disasters, terrorist attacks, or other emergencies, even in areas where power and communication has been disrupted. In 2010, mass notification system sales in the U.S. alone exceeded $1.2 billion (Source: IMS Research).

Additionally, LRAD® can be a critical part of the layered defense/escalation of force strategy for law enforcement and government agencies trying to control protests, riots, or other large crowd scenarios. LRAD Corp. has received substantial media coverage after its products were used for public safety in widely publicized events such as the G20 Summit in Pittsburgh during 2009 and the Occupy Wall Street movement in New York and Los Angeles in late 2011.

Commercial Security

The Company’s LRAD® products can help secure perimeters and protect infrastructure both on land and at sea. In the maritime setting, LRAD® technology has been used to secure ports and waterfront perimeters as well as to protect personal vessels and cruises ships against pirate attacks and other threats. The International Maritime Bureau (IMB) received reports of 439 pirate attacks globally during 2011, with 113 vessels fired upon, 176 ships boarded, 45 vessels hijacked, over 800 crew members taken hostage, and eight people killed. To date, LRAD® products have been used by the U.S. Navy, the South Korean Navy, and luxury cruise liners, among others, to successfully repel pirate attacks.

Follow Crystal Research on Facebook or Twitter to be among the first to receive updates and announcements on LRAD Corp.'s latest development initiatives.

 

Read More

Topics: Crystal Research Associates, LRAD, New Research

APDN’s Anti-Counterfeiting Technology Addresses New Federal Legislation

Posted by Colleen Koski

January 5, 2012 at 8:33 AM

A significant opportunity has arisen for Applied DNA Sciences (APDN-OTC) and its anti-counterfeiting and diversion efforts…

Read More

Topics: Crystal Research Associates, Newsworthy Events, Applied DNA Sciences

Content not found
Receive Our Research Notifications

About This Blog

We provide investor-based research and corporate communications services to companies worldwide. Visit our About Us page to learn more.

Posts by Date

see all

Posts by Topic